European Court Invalidates Enanta's Paxlovid Patent And Tosses Its Infringement Suit Against Pfizer

The Unified Patent Court ruled the '265 patent invalid, ending Enanta's infringement case covering 18 EU member states.

Share
European Court Invalidates Enanta's Paxlovid Patent And Tosses Its Infringement Suit Against Pfizer

The Unified Patent Court of the European Union on Thursday declared Enanta Pharmaceuticals' European patent invalid and ruled its infringement suit against Pfizer over the Covid antiviral Paxlovid unfounded. Enanta, which develops small molecule drugs for virology and immunology, disclosed the outcome in an 8-K filed the same day.

Validity decided, infringement fell with it

The court concluded that European Patent No. EP 4 051 265, known as the '265 patent, is invalid. Because the patent failed on validity, the court said the infringement claim had no basis, Enanta reported.

Enanta had sued Pfizer and certain of its subsidiaries, seeking a finding of liability for the manufacture, use and sale of Paxlovid, which pairs nirmatrelvir tablets with ritonavir tablets. The claim covered the 18 EU member states that participate in the court.

Pfizer had counterclaimed to have the patent revoked. A hearing on both the infringement action and the counterclaim took place on September 29, 2026, and the court released its decision on October 29, 2026.

A royalty company with its own pipeline

Enanta's revenue has long come from royalties, not from Paxlovid. It discovered glecaprevir, the hepatitis C antiviral that AbbVie sells in the combination treatment MAVYRET in the US and MAVIRET elsewhere, and substantially all of its royalty revenue since August 2017 has come from that treatment, according to its annual report.

Its own research targets respiratory syncytial virus, with two clinical-stage candidates, plus early-stage oral drugs for type 2 inflammatory diseases such as chronic spontaneous urticaria and atopic dermatitis. As of September 30, 2025, it held $188.9 million in cash, cash equivalents and short-term marketable securities.

The ruling ends the European case that Enanta brought against Pfizer over Paxlovid, a case heard in the court on September 29, 2026.

Sources

More on Enanta Pharmaceuticals

All Enanta Pharmaceuticals (ENTA) coverage →